Compare ITRG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | IRWD |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.5M | 741.8M |
| IPO Year | 2017 | 2009 |
| Metric | ITRG | IRWD |
|---|---|---|
| Price | $3.15 | $3.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $5.13 | $4.94 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $733.38 | $57.95 |
| Revenue Next Year | $46.00 | $4.39 |
| P/E Ratio | $45.07 | ★ $22.53 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.05 | $0.55 |
| 52 Week High | $4.87 | $5.78 |
| Indicator | ITRG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 37.17 |
| Support Level | $2.62 | $3.08 |
| Resistance Level | $3.30 | $3.53 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 1.55 | 41.36 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.